REAL CLEAR HEALTH: Price Controls Would Stifle Innovation, Reduce Access

Americans are right to be concerned about the high out-of-pocket costs of pharmaceuticals. But targeting America’s free enterprise system is the wrong solution. Putting bureaucrats abroad in charge of deciding how our drug market operates may save some money now, but it’ll hurt consumers in the long-run. This op-ed, published in Real Clear Health, explains the negative consequences of price controls on patients and innovation.

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin